Hospital-Based Vaccination Pathway — Competitive Intelligence Brief

Hospital-Based Vaccination Pathway (hospital-based-vaccination-pathway) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine various pathogens Immunology

Target snapshot

Hospital-Based Vaccination Pathway (hospital-based-vaccination-pathway) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hospital-Based Vaccination Pathway TARGET	hospital-based-vaccination-pathway	Pfizer	marketed	vaccine	various pathogens
Intravenous immune globulin G	Intravenous immune globulin G	Rutgers, The State University of New Jersey	marketed	Immunoglobulin replacement therapy / Immunomodulator	Multiple (polyclonal IgG antibodies targeting various pathogens and self-antigens)
Human immunoglobulin intravenous	Human immunoglobulin intravenous	Green Cross Corporation	phase 3	Immunoglobulin replacement therapy / Passive immunotherapy	Multiple (polyclonal IgG targeting various pathogens and immune targets)
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Meningococcal A+C vaccine	Meningococcal A+C vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Polysaccharide conjugate vaccine	Neisseria meningitidis serogroups A and C capsular polysaccharides
Meningococcal A conjugate vaccine	Meningococcal A conjugate vaccine	PATH	marketed	Conjugate vaccine	Neisseria meningitidis serogroup A polysaccharide capsule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class